Tiltan has developed a proprietary combinatorial drug therapy that consists of metronomic chemotherapy together with anti-angiogenic and immune-modulatory properties, for the treatment of cancer.
Tiltan's novelty is the re-purposing of four approved drugs, with known safety and pharmacokinetic profiles, to an optimized combined anti-angiogenic and immune-modulatory therapy in a unique regimen in terms of dose and scheduling.
Tiltan's drug combination platform can be optimized by adding other standard- of- care cancer drugs to expand the therapeutic potential to other cancer indications.
Tiltan's leading drug combination is TL-118, which is currently being evaluated in a phase IIb study for metastatic pancreatic cancer patients. The trial is no longer recruiting patients.